You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up here.
Another big win for Enhertu
The stuff I do for you, dear readers, because I love you: Work until 10:30 p.m. on Saturday night to finish a story on the Enhertu “ultra low HER2” breast cancer data from the Destiny-Breast06 trial. And then get up at the crack of dawn Sunday to attend the 7:30 a.m. special session that ASCO scheduled to show the data to the world.
No thanks needed, except of course, please read the Enhertu story that I worked so hard to write!
Click this link for the original source of this article.
Author: Adam Feuerstein, Matthew Herper, and Angus Chen
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.